{"id":"NCT04426890","sponsor":"Celltrion","briefTitle":"To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous Urticaria","officialTitle":"A Double-blind, Randomized, Active-controlled, Parallel Group, Phase 3 Study to Compare Efficacy and Safety of CT-P39 and Xolair in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-12-09","primaryCompletion":"2022-10-21","completion":"2023-04-27","firstPosted":"2020-06-11","resultsPosted":"2025-07-29","lastUpdate":"2025-07-29"},"enrollment":634,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Spontaneous Urticaria"],"interventions":[{"type":"BIOLOGICAL","name":"CT-P39","otherNames":["Omalizumab"]},{"type":"BIOLOGICAL","name":"EU-approved Xolair","otherNames":["Omalizumab"]}],"arms":[{"label":"Arm 1","type":"EXPERIMENTAL"},{"label":"Arm 2","type":"ACTIVE_COMPARATOR"},{"label":"Arm 2-1","type":"ACTIVE_COMPARATOR"},{"label":"Arm 2-2","type":"ACTIVE_COMPARATOR"},{"label":"Arm 3","type":"EXPERIMENTAL"},{"label":"Arm 4","type":"ACTIVE_COMPARATOR"}],"summary":"A Double-blind, Randomized, Active-controlled, Parallel Group, Phase 3 Study to Compare Efficacy and Safety of CT-P39 and Xolair in Patients with Chronic Spontaneous Urticaria Who Remain Symptomatic despite H1 antihistamine Treatment","primaryOutcome":{"measure":"Therapeutic Equivalence Based on Change From Baseline in ISS7 at Week 12 in 300 mg Groups","timeFrame":"Week 12","effectByArm":[{"arm":"Arm 1","deltaMin":-9.25,"sd":0.787},{"arm":"Arm 2","deltaMin":-9.96,"sd":0.791}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":6},"locations":{"siteCount":1,"countries":["Poland"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":203},"commonTop":["COVID-19","Nasopharyngitis","Injection site reaction","Headache","Upper respiratory tract infection"]}}